GSK’s Omjjara gains approval in Japan for myelofibrosis treatment
GSK has received approval from the Japan's Ministry of Health, Labour and Welfare (MHLW) for Omjjara to treat patients with myelofibrosis.
GSK has received approval from the Japan's Ministry of Health, Labour and Welfare (MHLW) for Omjjara to treat patients with myelofibrosis.
What's Your Reaction?
